Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases

Moonwalk Biosciences announced a $70 million Series B financing to advance adipose-targeted RNAi therapies for obesity and cardiometabolic diseases. The funding is a positive validation of the company’s therapeutic platform and supports further development in a large, competitive metabolic-disease market, though it is unlikely to have broad public-market impact.